It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

ANALYSIS

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
With debate on constitutional reform sidelined, has immigration law been a pyrrhic victory for Abe?

National / Politics | ANALYSIS Dec 10, 2018

With debate on constitutional reform sidelined, has immigration law been a pyrrhic victory for Abe?

by Tomohiro Osaki

As the extraordinary Diet session wrapped up, Abe found himself no closer to fulfilling his longtime ambition of amending the nation’s postwar Constitution.

Takeda downgrade looms after shareholders approve Shire deal

Business / Corporate | ANALYSIS Dec 6, 2018

Takeda downgrade looms after shareholders approve Shire deal

by Kevin Buckland and Lisa Du

Takeda Pharmaceutical Co. shareholders' approval of the $62 billion (about ¥7 trillion) acquisition of Shire PLC is good news for its bosses' ambitions to build a global drug giant — but bad news for its credit ratings. The backing of what will be the largest-ever ...

«527528529530531»

SUSTAINABLE JAPAN

Support our journalism

Staying informed during times of uncertainty is crucial, which is why The Japan Times is providing free access to select stories about the coronavirus pandemic. Please consider subscribing today and support our efforts to deliver the news that matters.
SUBSCRIBE NOW
The Japan Times circular logo

SPECIAL SUPPLEMENTS

Sponsored contents planned and edited by JT Media Enterprise Division.

広告出稿に関するおといあわせはこちらまで

Read more

SUPPLEMENTS BINDER

international-reports
  • Bridges by SMS
  • Global Insight
  • GMI Post
  • World Eye Reports
Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times